GenSight Biologics reports positive 72-week data from REVERSE Phase III clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)
• Clinically meaningful improvement of +15 ETDRS letters in visual acuity of treated eyes at Week 72
• Continuous bilateral improvement of both visual acuity and contrast sensitivity
• Significantly higher proportion of drug-treated eyes achieved clinically meaningful improvement in contrast sensitivity
• Sustained preservation of LHON-relevant retinal anatomy in treated eyes further demonstrates the neuroprotective effect of GS010
Paris, France, October 18, 2018, 7.30 am CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported additional results at Week 72 from the REVERSE Phase III clinical trial, which evaluates the safety and efficacy of a single intravitreal injection of GS010 (rAAV2/2-ND4) in 37 subjects whose visual loss due to 11778-ND4 Leber Hereditary Optic Neuropathy (LHON) commenced between 6 and 12 months prior to study treatment.
Please find the complete press release here